> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron beats Q2 estimates as Dupixent hits record $6B quarter
- URL: https://members.americanhealthintel.com/2026-08-02-ledger/
- Published: 2026-08-02T16:05:24.000Z
- Updated: 2026-08-02T16:05:24.000Z
- Description: Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Sunday, August 2, 2026 Regeneron beats Q2 estimates as Dupixent hits record $6B quarter Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Earnings Confidence: High Regeneron, the biotech behind blockbuster eczema and asthma drug Dupixent, beat Wall Street's second-quarter estimates on both revenue and profit, as Dupixent posted its biggest quarter ever. Revenue hit $4.29 billion, up 17%. Dupixent's global sales jumped 38% to $6.0 billion, a record, while Regeneron's own EYLEA HD and Libtayo each grew more than 30% and also hit new sales highs. Why it matters Regeneron's blowout quarter shows demand for its immunology and eye drugs keeps climbing, a sign biotech innovation is still commanding premium pricing. Watch whether Dupixent's growth holds as competitors enter the eczema and asthma space. Sources: [Globenewswire](https://www.globenewswire.com/news-release/2026/07/30/3335868/0/en/regeneron-reports-second-quarter-2026-financial-and-operating-results.html?ref=members.americanhealthintel.com) · [SEC](https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000023/exhibit991q22026.htm?ref=members.americanhealthintel.com) Other Confidence: High Wellstar Health System, the nonprofit hospital network that is one of Georgia's largest employers, is cutting 761 corporate and administrative jobs, about 2% of its workforce. The cuts hit corporate and shared-services functions and some administrative roles, not frontline caregivers. Wellstar says the move follows an industry-benchmark review meant to simplify its structure and speed decision-making. Why it matters A major nonprofit hospital system trimming corporate staff signals financial pressure even at large, established health systems. Watch whether other Georgia or regional systems follow with similar restructuring. Sources: [Fiercehealthcare](https://www.fiercehealthcare.com/providers/wellstar-health-system-lays-761-corporate-administrative-staff?ref=members.americanhealthintel.com) · [Beckershospitalreview](https://www.beckershospitalreview.com/finance/wellstar-cuts-761-jobs/?ref=members.americanhealthintel.com) Also today Guardian Dentistry Partners acquires 38-location Select Dental Management [Read](https://americanhealthintel.com/editions/2026-08-02-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#guardian-dentistry-select-dental-management-acquisition) FRONTIER SCAN: Knox Lane's $437M Cross Country Healthcare buyout [Read](https://americanhealthintel.com/editions/2026-08-02-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#knox-lane-cross-country-healthcare-staffing-buyout-frontier-scan) 364Records$28.6BEnforcement17Deadlines108Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-02-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |